Skip to main content
SpringerLink
Log in

Subjective Assessment of the Overactive Pelvic Floor

  • Chapter
The Overactive Pelvic Floor

  • 1570 Accesses

Abstract

Women with pelvic floor hyperactivity experience an array of associated symptoms that include bladder problems, pelvic pain, sexual dysfunction, and gastrointestinal disorders. Such patients are consistently undergoing thorough evaluations due to their complex presentation, the disorder’s uncertain etiology, alarming prevalence and significant impact on quality of life. Screening the appropriate patient population with validated questionnaires is essential and can help trigger effective communication between patients and their health care providers. This chapter explores the subjective tools established to assess patients with overactive pelvic floor disorders and aims to characterize the multiple approaches that have been established today.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hayden BT, de Ridder D, Freeman RM, et al. An International Urogynaecological Association (IUGA)/International Incontinence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26.

    Article  Google Scholar 

  2. Lowenstein L, Rickey L, Kenton K, et al. Reliability and responsiveness of the Urgency Severity and Life Impact Questionnaire (USIQ). Int Urogynecol J. 2012;23(2):193–6.

    Article  PubMed  Google Scholar 

  3. Chapple CR, Artibani W, Cardozo LD, et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005;95(3):335–40.

    Article  PubMed  Google Scholar 

  4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36.

    CAS  PubMed  Google Scholar 

  5. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6.

    Article  CAS  PubMed  Google Scholar 

  6. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306–14.

    Article  PubMed  Google Scholar 

  7. Coyne KS, Sexton CC, Vats V, et al. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.

    Article  PubMed  Google Scholar 

  8. Tang DH, Colayco DC, Khalaf KM, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int. 2013;113(3):484–91.

    Article  Google Scholar 

  9. Brubaker L. Urgency: the cornerstone symptom of overactive bladder. Urology. 2004;64:12–6.

    Article  PubMed  Google Scholar 

  10. Chapple CR, Drake MJ, Van Kerrebroeck P, et al. Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. BJU Int. 2014;113(5):696–703.

    Article  PubMed  Google Scholar 

  11. Freeman RM. How urgent is urgency? A review of current methods of assessment. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:93–5.

    Article  CAS  PubMed  Google Scholar 

  12. Robinson D, Cardozo L. Overactive bladder: diagnosis and management. Maturitas. 2012;71(2):188–93.

    Article  PubMed  Google Scholar 

  13. Cardozo L, Staskin D, Currie B, et al. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J. 2014;25:1655–63.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Basra R, Artibani W, Cardozo L, et al. Design and validation of a new screening instrument for lower urinary tract dysfunction: The Bladder Control Self-Assessment Questionnaire (B-SAQ). Eur Urol. 2007;52(1):230–7.

    Article  PubMed  Google Scholar 

  15. Cruz F, Denys P, Cidre MJ, et al. Patient attitudes and patterns of treatment utilization in a European population with overactive bladder. Poster presented at the European Association of Urology (EAU) 27th annual congress, Paris, France; 2012. p. 24–28.

    Google Scholar 

  16. Sahai A, Dowson C, Cortes E, et al. Validation of bladder control self-assessment questionnaire (B-SAQ) in men. BJU Int. 2014;113(5):783–8.

    Article  PubMed  Google Scholar 

  17. Burks J, Chancellor M, Bates D, et al. Development and validation of the actionable multiple sclerosis bladder health screening tool. Int J MS Care. 2013;15(4):182–92.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Michel MC, Chapple CR. Basic mechanisms of urgency: preclinical and clinical evidence. Eur Urol. 2009;56:298–307.

    Article  PubMed  Google Scholar 

  19. Dmochowski R, Heit M, Sand P. The effect of anticholinergic therapy on urgency severity in patients with overactive bladder: clinical assessment of a newly validated tool. Neurourol Urodyn. 2003;22:411–2.

    CAS  Google Scholar 

  20. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol. 2005;56:298–307.

    Google Scholar 

  21. Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int. 2005;95:591–6.

    Article  PubMed  Google Scholar 

  22. Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin Ther. 2002;24:616–28.

    Article  CAS  PubMed  Google Scholar 

  23. Van Kerrebroeck P, Kreder K, Jonas U, et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology. 2001;57:414–21.

    Article  PubMed  Google Scholar 

  24. Blaivas JG, Panagopoulos G, Weiss JP, et al. The urgency perception score: validation and test-retest. J Urol. 2007;177:199–202.

    Article  PubMed  Google Scholar 

  25. Notte SM, Marshall TS, Lee M, et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder.

    Google Scholar 

  26. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol. 2005;48:464–70.

    Article  CAS  PubMed  Google Scholar 

  27. Chapple CR, Amarenco G, Lopez Aramburu MA, et al. A proof-of-concept study: Mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32:1116–22.

    Article  CAS  PubMed  Google Scholar 

  28. Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67:619–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Cardozo L, Mikulas G, Amarenco T, et al. Total Urgency score (TUS) as a measure of frequency and urgency in SUNRISE. Urology. 2010;76(Suppl. 3):S92. Abstract UP-2.35.

    Google Scholar 

  30. Van Kerrebroeck PEV, Haab F, Angulo JC, et al. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage LUTS: results from phase 2, dose-finding study (SATURN). Eur Urol. 2013;64:398–407.

    Article  PubMed  Google Scholar 

  31. Van Kerrebroeck P, Chapple C, Drogendijk T, et al. Combination therapy with solifenacin and tamsuolosin OCAS™ in a single tablet for lower urinary track symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64:1003–12.

    Article  PubMed  Google Scholar 

  32. Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Qual Life Res. 1994;3:291–306.

    Article  CAS  PubMed  Google Scholar 

  33. Robinson D, Pearce KF, Preisser JS, et al. Relationship between patient reports of urinary incontinence symptoms and quality of life measures. Obstet Gynecol. 1998;91:224–8.

    Article  CAS  PubMed  Google Scholar 

  34. Hagen S, Hanley J, Capewell A. Test-retest reliability, validity, and sensitivity to change of urogenital distress inventory and the incontinence impact questionnaire. Neurourol Urodyn. 2002;21:534–9.

    Article  PubMed  Google Scholar 

  35. Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Neurourol Urodyn. 1995;14:131–9.

    Article  CAS  PubMed  Google Scholar 

  36. Dugan E, Cohen SJ, Robinson D, et al. The quality of life of older adults with urinary incontinence: determining generic and condition specific predictors. Qual Life Res. 1998;7(4):337–44.

    Article  CAS  PubMed  Google Scholar 

  37. Kelleher CJ, Cardozo LD, Toozs-Hobson PM. Quality of life and urinary incontinence. Curr Opin Obstet Gynecol. 1995;7:404–8.

    Article  CAS  PubMed  Google Scholar 

  38. Badia LX, Castro DD, Conejero SJ. Validity of the King’s Health Questionnaire in the assessment of quality of life of patients with urinary incontinence. The King’s Group. Med Clin (Barc). 2000;114:647–52.

    Article  Google Scholar 

  39. Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol. 2003;188:1244–8.

    Article  PubMed  Google Scholar 

  40. Okamura K, Usami T, Nagahama K, et al. “Quality of life” assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King’s Health Questionnaire. Eur Urol. 2002;41:411–9.

    Article  PubMed  Google Scholar 

  41. Wyman JF, Harkins SQ, Taylor JR, Fantl AJ. Psychosocial impact of urinary incontinence in women. Obstet Gynecol. 1987;70(3 Pt 1):378–81.

    CAS  PubMed  Google Scholar 

  42. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003;62:237–42.

    Article  PubMed  Google Scholar 

  43. Sander P, Thyssen H, Lose G, Andersen J. The effect of a vaginal device on urinary leakage and quality of life of women with stress urinary incontinence. Ugeskr Laeger. 2000;162:3038–41.

    CAS  PubMed  Google Scholar 

  44. Andrew J, Yunker A, Reynolds WS, et al. Noncyclic chronic pelvic pain therapies for women: comparative effectiveness. Rockville: AHRQ Comparative Effectiveness Reviews; 2012.

    Google Scholar 

  45. Romao AP, Gorayeb R, Romao GS, et al. Chronic pelvic pain: multifactorial influences. J Eval Clin Pract. 2011;17(6):1137–9.

    Article  PubMed  Google Scholar 

  46. Mathias SK, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life and economic correlates. Obstet Gynecol. 1996;87(3):321–7.

    Article  CAS  PubMed  Google Scholar 

  47. Reiter RC, Gambone JC. Demographic and historic variables in women with idiopathic chronic pelvic pain. Obstet Gynecol. 1990;75(3 Pt 1):428–32.

    CAS  PubMed  Google Scholar 

  48. Neelakantan D, Omojole F, Clark TJ, et al. Quality of life instruments in studies of chronic pelvic pain: a systematic review. J Obstet Gynecol. 2004;24(8):851–8.

    Article  CAS  Google Scholar 

  49. Jones G, Kennedy S, Barnard A, et al. Development of an endometriosis quality-of-life instrument: the Endometriosis Health Profile-30. Obstet Gynecol. 2001;98(2):258–64.

    Article  CAS  PubMed  Google Scholar 

  50. Rourke W, Khan SA, Ahmed K, et al. Painful bladder syndrome/interstitial cystitis: aetiology, evaluation and management. Arch Ital Urol Androl. 2014;86(2):126–31.

    Article  PubMed  Google Scholar 

  51. van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53:60–7.

    Article  PubMed  Google Scholar 

  52. Parsons JK, Kurth K, Sant GR. Epidemiologic issues in interstitial cystitis. Urology. 2007;69(4 Suppl):5–8.

    Article  PubMed  Google Scholar 

  53. O’Leary MP, Sant GR, Fowler Jr FJ, et al. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5A Suppl):58–63.

    Article  PubMed  Google Scholar 

  54. Sirinian E, Azevedo K, Payne CK. Correlation between 2 interstitial cystitis symptom instruments. J Urol. 2005;173(3):835–40.

    Article  PubMed  Google Scholar 

  55. Lubeck DP, Whitmore K, Sant GR, et al. Psychometric validation of the O’Leary-Sant interstitial cystitis symptom index in a clinical trial of pentosan polysulfate sodium. Urology. 2001;57(6 Suppl 1):62–6.

    Article  CAS  PubMed  Google Scholar 

  56. Clemens JQ, Clahoun EA, Litwin MS, et al. Validation of a modified National Institutes of Health chronic prostatitis symptom index to assess genitourinary pain in both men and women. Urology. 2009;74(5):983–7.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.

    Article  CAS  PubMed  Google Scholar 

  58. Meyer-Bahlbourg HF, Dolezal C. The female sexual function index: a methodological critique and suggestions for improvement. J Sex Marital Ther. 2007;33(3):217–24.

    Article  Google Scholar 

  59. Weigel M, Meston C, Rosen R. The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.

    Article  Google Scholar 

  60. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. 2000.

    Google Scholar 

  61. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. 2013.

    Google Scholar 

  62. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA. 1994;272(22):1749–56.

    Article  CAS  PubMed  Google Scholar 

  64. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. Gen Hosp Psychiatry. 2006;28(1):71–7.

    Article  PubMed  Google Scholar 

  65. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J. Validity and utility of the PRIME-MD Patient Health Questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol. 2000;183(3):759–69.

    Article  CAS  PubMed  Google Scholar 

  66. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the gad-7. Arch Intern Med. 2006;166(10):1092–7.

    Article  PubMed  Google Scholar 

  67. Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care. 2008;46(3):266–74.

    Article  PubMed  Google Scholar 

  68. Weathers FW, Litz BT, Keane, TM, et al. The PTSD checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD. 2013. www.ptsd.va.gov.

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Rambam Health Care Campus, HaAliya HaShniya Street 8, Haifa, 3109601, Israel

    Lior Lowenstein M.D., M.S.

  2. Department of Obstetrics and Gynecology, Lenox Hill Hospital, New York, NY, USA

    Moti Gulersen M.D., M.Sc.

  3. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Amy Lehrner Ph.D.

  4. Trauma & Readjustment Services (PTSD), James J. Peters VA Medical Center, Bronx, NY, USA

    Amy Lehrner Ph.D.

Authors
  1. Lior Lowenstein M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moti Gulersen M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy Lehrner Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lior Lowenstein M.D., M.S. .

Editor information

Editors and Affiliations

  1. Urogynecology and Pelvic Floor Service, Assaf Harofeh Medical Center, Zerifin, Israel

    Anna Padoa

  2. Inner Stability, Ltd, Beit Shemesh, Israel

    Talli Y. Rosenbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lowenstein, L., Gulersen, M., Lehrner, A. (2016). Subjective Assessment of the Overactive Pelvic Floor. In: Padoa, A., Rosenbaum, T. (eds) The Overactive Pelvic Floor. Springer, Cham. https://doi.org/10.1007/978-3-319-22150-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22150-2_10

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22149-6

  • Online ISBN: 978-3-319-22150-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation